MB Pharma's Microbial Collection as a Source of New Enzybiotics

a 2022

MB Pharma's Microbial Collection as a Source of New Enzybiotics

ČUPROVÁ, Kristína, Martin BENEŠÍK, Tomáš BARTEJS, Tereza ŠOPÍKOVÁ, Tibor BOTKA et. al.

Základní údaje

Originální název

MB Pharma's Microbial Collection as a Source of New Enzybiotics

Autoři

ČUPROVÁ, Kristína, Martin BENEŠÍK, Tomáš BARTEJS, Tereza ŠOPÍKOVÁ, Tibor BOTKA, Lenka JANALOVÁ a Marek MOŠA

Vydání

Viruses of Microbes 2022, Guimarães, Portugal, 2022, 2022

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

10600 1.6 Biological sciences

Stát vydavatele

Portugalsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Viruses of Microbes 2022

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova anglicky

enzybiotics; antimicrobials; prediction

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 17. 10. 2022 17:08, Mgr. Tibor Botka, Ph.D.

Anotace

V originále

MB Pharma and FAGOFARMA are trying to build up a collection of microbes that could be a source of new antimicrobials. Not just phages from this collection, killing strains of Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, Aeromonas salmonicida, Cutibacterium acnes etc., but also their specific enzymes such as peptidoglycan hydrolases could be used. Moreover, genes encoding bacteriocins, bacterial cell wall-degrading enzymes and prophage endolysins were found in the genomes of clinical bacterial isolates and propagation strains from the collection. All these enzymes could be used as enzybiotics – a tool to fight microbial infections. More than 40 microbial genomes from the company's collection were automatically annotated using RAST and analysed. Hypothetical peptidoglycan hydrolases were found and compared with already identified endolysins. Tools such as HHpred, InterProScan and SMART were used to characterize their functional domains in more detail. Relatively low diversity of endolysins was observed in S. aureus, C. acnes or P. aeruginosa phages, whereas higher diversity was in K. pneumoniae phages. Some endolysins have been well described previously, such as LysK of S. aureus phage K, but others are novel. In addition, prophage endolysins were found in the bacterial genomes. In P. larvae, where only one endolysin was already described, a different hypothetical endolysin was identified in this work. Bacterial and phage genomes represent a great source of new antibacterial proteins whose activity needs to be proven experimentally. Several proteins, which could be used as enzybiotics, were identified in this research. Their modifications, such as addition of tags for destabilization and transmembrane transfer, could improve their activity, especially against Gram-negative bacteria.

Citovat

ČUPROVÁ, Kristína, Martin BENEŠÍK, Tomáš BARTEJS, Tereza ŠOPÍKOVÁ, Tibor BOTKA, Lenka JANALOVÁ a Marek MOŠA. MB Pharma's Microbial Collection as a Source of New Enzybiotics. In Viruses of Microbes 2022, Guimarães, Portugal, 2022. 2022.

@proceedings{2225527,
   author = {Čuprová, Kristína and Benešík, Martin and Bartejs, Tomáš and Šopíková, Tereza and Botka, Tibor and Janalová, Lenka and Moša, Marek},
   booktitle = {Viruses of Microbes 2022, Guimarães, Portugal, 2022},
   keywords = {enzybiotics; antimicrobials; prediction},
   language = {eng},
   title = {MB Pharma's Microbial Collection as a Source of New Enzybiotics},
   url = {https://skyros-congressos.pt/vom2022/},
   year = {2022}
}

TY  - CONF
ID  - 2225527
AU  - Čuprová, Kristína - Benešík, Martin - Bartejs, Tomáš - Šopíková, Tereza - Botka, Tibor - Janalová, Lenka - Moša, Marek
PY  - 2022
TI  - MB Pharma's Microbial Collection as a Source of New Enzybiotics
KW  - enzybiotics
KW  - antimicrobials
KW  - prediction
UR  - https://skyros-congressos.pt/vom2022/
N2  - MB Pharma and FAGOFARMA are trying to build up a collection of microbes that could be a source of new antimicrobials. Not just phages from this collection, killing strains of Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, Aeromonas salmonicida, Cutibacterium acnes etc., but also their specific enzymes such as peptidoglycan hydrolases could be used. Moreover, genes encoding bacteriocins, bacterial cell wall-degrading enzymes and prophage endolysins were found in the genomes of clinical bacterial isolates and propagation strains from the collection. All these enzymes could be used as enzybiotics – a tool to fight microbial infections. More than 40 microbial genomes from the company's collection were automatically annotated using RAST and analysed. Hypothetical peptidoglycan hydrolases were found and compared with already identified endolysins. Tools such as HHpred, InterProScan and SMART were used to characterize their functional domains in more detail. Relatively low diversity of endolysins was observed in S. aureus, C. acnes or P. aeruginosa phages, whereas higher diversity was in K. pneumoniae phages. Some endolysins have been well described previously, such as LysK of S. aureus phage K, but others are novel. In addition, prophage endolysins were found in the bacterial genomes. In P. larvae, where only one endolysin was already described, a different hypothetical endolysin was identified in this work. Bacterial and phage genomes represent a great source of new antibacterial proteins whose activity needs to be proven experimentally. Several proteins, which could be used as enzybiotics, were identified in this research. Their modifications, such as addition of tags for destabilization and transmembrane transfer, could improve their activity, especially against Gram-negative bacteria.
ER  -

ČUPROVÁ, Kristína, Martin BENEŠÍK, Tomáš BARTEJS, Tereza ŠOPÍKOVÁ, Tibor BOTKA, Lenka JANALOVÁ a Marek MOŠA. MB Pharma's Microbial Collection as a Source of New Enzybiotics. In \textit{Viruses of Microbes 2022, Guimarães, Portugal, 2022}. 2022.

Podrobný výpis o publikaci